GSK withstands Advair generics, thanks to new respiratory meds and Shingrix

24th July 2019 Uncategorised 0

In its first full quarter under assault from generic Advair, GlaxoSmithKline still managed to grow sales, thanks to its newer respiratory drugs and the fast-growing Shingrix vaccine. Plus, its cancer pipeline—one of GSK’s top hopes for the future—is taking shape.

More: GSK withstands Advair generics, thanks to new respiratory meds and Shingrix
Source: fierce